Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche and Chugai granted NICE recommendation for RoActemra

Roche and Chugai granted NICE recommendation for RoActemra

5th July 2010

Roche and development partner Chugai have been granted a restricted National Institute for Health and Clinical Excellence (NICE) recommendation for their rheumatoid arthritis drug RoActemra (tocilizumab).

The regulatory body has recommended that a combination therapy of RoActemra and methotrexate be used in England and Wales among patients who are unable to benefit from a MabThera treatment.

This comes in response to data from clinical studies which showed the effectiveness of the Roche/Chugai treatment when compared to placebo.

Roche and Chugai are now calling on NICE to grant a wider recommendation to the drug for all patients who do not respond to disease-modifying anti-rheumatic drugs or anti-TNF agents.

Dr Andrew Ostor, consultant rheumatologist and associate lecturer at Addenbrooke’s Hospital, said: “It would be ideal to use tocilizumab across the board, as in Scotland and the rest of Europe, but as the recommendation stands it is a very encouraging step in the right direction.”

This comes after a study published last month showed that RoActemra could also potentially provide benefits for systemic juvenile idiopathic arthritis sufferers.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.